Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | CSO | February 13, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date February 13, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.85 · Expires 2034-02-13 | Direct | 90,000 |
Reported balance
After 2024-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-13 · Grant · Acquired 90,000 · Balance 90,000 F1: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 45,000 |
Reported balance
After 2024-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-13 · Grant · Acquired 45,000 · Balance 45,000 F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
F3: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 16, 2024 16:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016192 · ownership.xml · derivative · entry 2 Marlowe Jennifer · CIK 0001955871 · CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 16:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0000950170-24-016192 · ownership.xml · derivative · entry 1 Marlowe Jennifer · CIK 0001955871 · CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 19:30 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 4,890 | $2.77 | $13,524.76 |
DisclosureSEC source: 0000950170-23-068063 · ownership.xml · nonDerivative · entry 2 Marlowe Jennifer · CIK 0001955871 · CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,998 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:30 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 11,888 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068063 · ownership.xml · derivative · entry 3 Marlowe Jennifer · CIK 0001955871 · CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,667 Underlying: Common Stock · 11,888 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:30 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 11,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-068063 · ownership.xml · nonDerivative · entry 1 Marlowe Jennifer · CIK 0001955871 · CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:53 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 47,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037688 · doc4.xml · derivative · entry 2 Marlowe Jennifer · CIK 0001955871 · CSO, FA & Cardiac 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,555 Underlying: Common Stock · 47,555 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:53 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 95,110 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0000899243-22-037688 · doc4.xml · derivative · entry 1 Marlowe Jennifer · CIK 0001955871 · CSO, FA & Cardiac 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,110 Underlying: Common Stock · 95,110 shares Expires 2032-12-02 F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.